Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar) in Adult Patients With Uveal Melanoma and Metastatic Dissemination (O-Mel-Sora)

Next Previous
Search
Trial Profile

Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar) in Adult Patients With Uveal Melanoma and Metastatic Dissemination (O-Mel-Sora)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Uveal melanoma
  • Focus Therapeutic Use

Most Recent Events

  • 02 Jun 2016 Primary endpoint has been met. (non-tumor progression rate), as per an article published in the British Journal of Cancer.
  • 02 Jun 2016 Status changed from active, no longer recruiting to completed, as per an article published in the British Journal of Cancer.
  • 02 Jun 2016 Results published in the British Journal of Cancer

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top